JMP Securities Upgrades BioCryst Pharma (BCRX) to Market Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $7.78 +0.39%
Rating Summary:
16 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 2 | Down: 5 | New: 5
Rating Summary:
16 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 2 | Down: 5 | New: 5
Join SI Premium – FREE
JMP Securities upgraded BioCryst Pharma (NASDAQ: BCRX) from Market Perform to Market Outperform with a price target of $3.00.
For an analyst ratings summary and ratings history on BioCryst Pharma click here. For more ratings news on BioCryst Pharma click here.
Shares of BioCryst Pharma closed at $2.04 yesterday.
For an analyst ratings summary and ratings history on BioCryst Pharma click here. For more ratings news on BioCryst Pharma click here.
Shares of BioCryst Pharma closed at $2.04 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BNP Paribas Exane Upgrades Tesla (TSLA) to Neutral
- CLSA Upgrades KEI Industries Ltd (KEII:IN) to Outperform (2)
- BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE
Create E-mail Alert Related Categories
Hot Upgrades, UpgradesRelated Entities
JMP SecuritiesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
